Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for symptomatic non-obstructive hypertrophic cardiomyopathy
ISRCTN38776134Phase 2Recruiting
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of azacitidine in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Belfast Health and Social Care Trust. Primary endpoint: Safety of azacitidine measured using incidence of dose-limiting toxicity. Started Jun 2026; status: recruiting.
02
Drugs
azacitidine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ISRCTN38776134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38776134.